Industry Symposium: Pathways to better outcomes in rheumatic disease

Sponsored by Eli Lilly & Company


Date: Wednesday 10 April 2019
Time: 1300-1430
Location: Great Hill, BCEC

Chair
Prof Peter Nash, Australia

Speakers
Prof Peter Nash, Australia
Prof Andrew Östör, Australia
Dr Lars Erik Kristensen, Denmark

Description

This Lilly satellite symposium, “Pathways to better outcomes in rheumatic disease” will explore the integrated approach to improving our understanding of the impact of specific domains of chronic systemic disease, like Rheumatoid Arthritis, on the every-day-life of our patients.

The expert panel of presenters will review the recent improvements in patient management, as well as those areas that remain open to improvement, in the context of the current and emerging molecular mechanism of JAK inhibition and IL17 inhibition.

The symposium will be chaired by Prof. Peter Nash, from Australia, and will address three key areas:

  1. Can we improve patients’ outcomes in Rheumatoid and Psoriatic Arthritis?
    Speaker: Prof Andrew Östör, from Australia, will explore the role of the Patient-reported Outcomes and discuss how they can influence the different treatments options in light of shared decision-making.
  2. JAK inhibitors: Challenging the treatment paradigm in Rheumatoid Arthritis

    Speaker: TBC. Taking the patients view into consideration, the speaker will discuss whether the treatment paradigm for RA is adequate in 2019

  3. Treat to target in Psoriatic Arthritis: Translating the SPIRIT programme into clinical practice

    Speaker: Dr. Lars Erik Kristensen, from Denmark, will discuss treat to target in the context of the patient with PsA and review the data from the SPIRIT trial programme in clinical practice.

The symposium will close with a panel discussion for any unanswered questions.

We hope that you find this symposium a valuable forum for discussing the impact and areas of improvement in the treatment of rheumatic disease.

Program

Wednesday 10 April 2019
Time Topic Speaker
1300-1305 Welcome and introduction Prof Peter Nash
1305-1325 Can we improve patients’ outcomes in Rheumatoid and Psoriatic Arthritis? Prof Andrew Östör
1325-1345 JAK inhibitors: Challenging the treatment paradigm in Rheumatoid Arthritis TBC
1345-1405 Treat to target in Psoriatic Arthritis: Translating the SPIRIT programme into clinical practice Dr Lars Erik Kristensen
1405-1430 Panel discussion and Q&A All panel
1430 Symposium close